Cambridge Regulatory Services
|Industry||Regulatory Affairs, MAA, eCTD, Pharmacovigilance, DCP, Readability testing, and PIL user testing|
|Headquarters|| 2 Cabot House
Compass Point Business Park St Ives PE27 5JL Cambridgeshire (UK)
|Number of employees||11-50 employees|
- 1 Overview
- 2 Controversies
- 3 Top 5 Recent Tweets
- 4 Top 5 Recent News Headlines
- 5 Top 5 Lifetime Tweets
- 6 Top 5 Lifetime News Headlines
- 7 References
Cambridge Regulatory Services is a full service regulatory affairs consultancy helping pharmaceutical companies get their medicines to market faster. Help comes in many forms including advice, strategic planning, dossier preparation, management of submissions and all compliance issues.
The company is proud of the many benefits in working with them which are as follows:
- Fixed price option available
- Service Continuity
- Project Progress Reports
- Knowledgeable and experienced team (including Ex Regulators)
- World Wide cover
- Delivering your projects on time
Cambridge Regulatory Services has gained a reputation for delivering projects on time and within budget for its clients across the world.
Relentlessly striving to exceed their clients’ expectations, Cambridge Regulatory Services enables you to remain focused on your key objectives whilst our team of professionals takes care of your short-term or long-term regulatory needs.
Top 5 Recent Tweets
|April 13, 2021||andrewsibley15||@cambridge_peter @marcsaysmarc @HWick_Chris @PeteSchofield6 @Chloe0069 @ClareAdams @jJimCormeilles @Aspie66… https://t.co/sAmYqHV5Mo|
Top 5 Recent News Headlines
1. EMA Regulatory Guidance for industry to prepare for the UK’s withdrawal from the EU
Thursday 1st of June 2017 - http://www.cambreg.co.uk/news/ema-regulatory-guidance-industry-prepare-uks-withdrawal-eu/
The European Medicines Agency (EMA) and the European Commission have published guidance to help pharmaceutical companies to prepare for the United Kingdom's withdrawal from the European Union. The guidance relates to both human and veterinary medicines.
Marketing authorisation holders of centrally authorised medicinal products for human and veterinary use are reminded of certain legal repercussions, which need to be considered.
3. New MedRegs blog
MHRA has launched an official blog providing expert insight into the latest regulatory thinking and all aspects of medicines regulation.
Thursday 9th of February 2017 - http://www.cambreg.co.uk/news/changes-mhra-payment-fees/